The clinical outcomes of medical therapies in chronic rhinosinusitis are independent of microbiomic outcomes: a double-blinded, randomised placebo-controlled trial/Experiment 1

EditHistoryDelete

Mark reviewed

Your review change was submittedDuplicate this ExperimentAdd a new Signature

Needs review

Curated date: 2022/02/24

Curator: Maryemzaki

Revision editor(s): LGeistlinger, Lwaldron, Maryemzaki, Aiyshaaaa, Victoria

Subjects

Location of subjects

Finland

Host species Species from which microbiome was sampled. Contact us to have more species added.

Homo sapiens

Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology

Middle nasal meatus Middle meatus,Middle meatus of the nose,Middle nasal meatus,middle nasal meatus

Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology

Chronic rhinosinusitis chronic rhinosinusitis,chronic sinusitis,sinusitis, chronic,Chronic rhinosinusitis

Group 0 name Corresponds to the control (unexposed) group for case-control studies

Healthy controls-without polyps

Group 1 name Corresponds to the case (exposed) group for case-control studies

Patients with chronic rhinosinusitis

Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group

CRS patients diagnosed as per the criteria outlined in the Euro- pean Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) 2012

Group 0 sample size Number of subjects in the control (unexposed) group

50

Group 1 sample size Number of subjects in the case (exposed) group

50

Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)

Patients who were on any oral steroid, topical steroid or oral antibiotic in a 6-weeks period prior to enrollment, below the age of 18, had a history of sinus surgery, documented doxycycline or steroid allergy, using CYP450 inhibitors, immunosuppression, uncontrolled diabetes, were all excluded.

Lab analysis

Sequencing type

16S

16S variable region One or more hypervariable region(s) of the bacterial 16S gene

V3-V4

Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance

Illumina

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).

relative abundances

Statistical test

ANOVA

Significance threshold p-value or FDR threshold used for differential abundance testing (if any)

0.05